Kishore Hotha
President Dr. Hotha’s
Life Sciences LLC
Dr. Kishore Hotha is a distinguished leader in the pharmaceutical, biotech, and CDMO sectors, with a strong track record in advancing drug substance and product development across small and large molecules, including Antibody-Drug Conjugates (ADCs), oligonucleotides, peptides, and complex formulations. Throughout his career, he has supported more than 100 global clients and contributed to more than 100 research articles, playing a pivotal role in over 90 IND, NDA, and ANDA submissions from concept through commercialization.
Currently, Dr. Hotha is the President of Dr. Hotha’s Life Sciences LLC, a consulting firm focused on simplifying complex CMC and analytical challenges. Previously, he served as Global Vice President at Veranova, where he led global laboratory operations across multiple sites, and held senior leadership roles at Lupin and Dr. Reddy’s Laboratories. With his extensive scientific expertise and industry influence, Dr. Hotha continues to help shape modern CMC strategy and pharmaceutical innovation.
Harch Ooi
Vice President of Manufacturing and Chemistry IsoBio, Inc.
Harch Ooi, Ph.D., has over 17 years experience working on antibody–drug conjugates (ADCs) within the biotech and pharmaceutical industry. With extensive experience in drug-linker chemistry, external manufacturing, and CMC strategy, he has supported multiple programs from preclinical through to commercial stages.
He has led global external manufacturing organizations at Seagen and Pfizer, overseen high-potency drug-linker, API, and drug product operations, and managed long-term partnerships with CMOs worldwide. Now, as Vice President of Manufacturing and Chemistry at IsoBio, he applies his ADC expertise to targeted radioligand therapies—combining technical knowledge, operational judgment, and a clear understanding of what it takes to deliver these therapies at scale.
Krzysztof Brzozka
Chief Scientific Officer and Executive Vice President at Ryvu Therapeutics
Krzysztof Brzozka, PhD, MBA is Chief Scientific Officer and Executive Vice President at Ryvu Therapeutics, where he leads oncology drug discovery and early clinical development. Over 15+ years, he has designed and advanced targeted cancer therapies spanning synthetic lethality, immuno-oncology, and next-generation ADC programs. At Ryvu, he has built and mentored a 150+ scientist R&D organization and helped progress first-in-class programs into clinical trials, including a dual PIM/FLT3 inhibitor (SEL24/MEN1703) and a CDK8 inhibitor (SEL120/RVU120), while contributing to the identification of multiple additional clinical candidates. He has also led strategic research partnerships with global biopharma organizations including BioNTech, Exelixis, Merck, and H3 Biomedicine, driving innovation through collaboration. Krzysztof holds a PhD in Molecular Biology and an MBA, and has co-authored 100+ publications and presentations (4,500+ citations) in leading journals. He is passionate about developing talent and translating breakthrough science into patient impact.
Ryan Holmes
Associate Director of Chemistry, Prelude Therapeutics
Ryan Holmes earned his BS in Chemistry and Biochemistry from Worcester Polytechnic Institute in 2015 and his PhD in Organic Chemistry from Yale University, where he trained under Prof. Seth Herzon and conducted research on the enantioselective synthesis of the complex tetraterpenoid natural product (–)-gukulenin A. Following his doctoral studies, he entered industry and joined the medicinal chemistry department at Prelude Therapeutics, where he has contributed to the discovery and development of small-molecule inhibitors, heterobifunctional degraders, and antibody–drug conjugates.
Ryan currently serves as Associate Director of Chemistry at Prelude Therapeutics, leading medicinal chemistry and bioconjugation efforts focused on the discovery of novel ADC payloads and linker–payload architectures. He is an active contributor to the scientific community as a co-inventor on multiple patents, an author of peer-reviewed publications, and a mentor to early-career scientists.
